Forodesine and nelarabine (the pro-drug of ara-G) are two nucleoside analogues with promising anti-leukemic activity. To better understand which pediatric patients might benefit from forodesine or nelarabine (ara-G) therapy, we investigated the in-vitro sensitivity to these drugs in 96 diagnostic pediatric leukemia patient samples and the mRNA expression levels of different enzymes involved in nucleoside metabolism.
INTRODUCTION
Leukemia is the most common childhood malignancy, and the general incidence in both adults and children to develop acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) is approximately 1 per 100,000 and 2-3 per 100,000, respectively. Although overall cure rates have been improved over the last decades, still about 20% of children with acute lymphoblastic leukemia (ALL) and 40% of children with acute myeloid leukemia (AML) eventually die from their disease 1,2 . In adults, the prognosis is worse with a survival below 60% in ALL 3 and 50% in AML 4 , indicating that there is still a great need for better therapy.
Currently, purine nucleosides analogues are in clinical trials for different types of leukemia including clofarabine, forodesine (BCX-1777/Immucillin H) and nelarabine (506U78/Arranon/Atriance) the latter being the prodrug for 9-β-D-arabinofuranosylguanine (ara-G).
Forodesine is a non-cleavable inosine analogue developed to bind and inhibit the purine nucleoside phosphorylase (PNP) enzyme
5
. PNP normally degrades excess of intracellular deoxyguanosine (dGuo) into guanosine and deoxyribose-1-phosphate through phosphorylysis. dGuo is continuously produced in the body as the result of DNA degradation during cellular turnover. Inhibition of PNP by forodesine results in the intracellular accumulation of dGuo. DGuo is rapidly phosphorylated to deoxyguanosine triphosphate (dGTP) in the purine salvage pathway leading to dGTP accumulation 6, 7 . High intracellular
To better predict which patients might benefit from forodesine or nelarabine treatment, we investigated the in-vitro sensitivity to forodesine or ara-G in pediatric ALL and AML diagnostic patient samples. Forodesine toxicity was investigated in relation to intracellular accumulation of dGTP levels. We also investigated potential mechanisms that may be responsible for differences in drug sensitivity among patient samples. To this end, we measured mRNA expression levels of proteins that are involved in purine metabolism and uptake (Figure 1) . In addition, we tested whether forodesine had a synergistic or antagonistic effect with 7 commonly used drugs in leukemia treatment.
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MATERIALS & METHODS Patient Material
Fresh or viably frozen bone marrow or peripheral blood samples from a total of 96 de novo, untreated pediatric acute leukemia patients were used, comprising 36 T-ALL, 43 BCP-ALL and 17 AML samples. All samples were tested for forodesine cytotoxicity, whereas additional assays were performed on the same samples based on the availability of material. The patients' parents or legal guardians provided informed consent to use leftover diagnostic patient biopsies for research in accordance with the Institutional Review Board of the Erasmus MC Rotterdam and in accordance with the Declaration of Helsinki. Leukemic cells were isolated and enriched as previously described 25 . All resulting samples contained ≥90% leukemic cells, as determined morphologically by May-Grünwald-Giemsa-stained cytospins (Merck, Darmstadt, Germany) and were viably frozen in liquid nitrogen as described earlier 25 .
Cell lines

T-ALL cell lines (CCRF-CEM, LOUCY, BE-13, MOLT-4, PEER, KARPAS-45, MOLT-3,
JURKAT, HPB-ALL, PF-382) were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), and cultured under recommended conditions.
Assessment of PNP inhibition by forodesine (dGuo measurements)
The efficacy of forodesine to inhibit phosphorylysis of dGuo into guanosine and deoxyribose-1-phosphate by PNP was assessed in 4 pediatric T-ALL and 2 pediatric BCP-ALL patient samples. For this, the decrease in dGuo concentration was measured over time in the supernatant of cell cultures that were treated with varying concentrations of forodesine. Cells were cultured in RPMI 1640 Dutch modification without L-glutamine, 20% fetal calf serum, 2 mM L-glutamine (Invitrogen), 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml sodium selenite (ITS media supplement; Sigma, St Louis MO, USA), 100 IU/ml penicillin, 100 μg/ml streptomycin, 0.125 μg/ml fungizone and 0.2 mg/ml gentamycin (Invitrogen) at a analysis. dGuo levels were analyzed by high-performance liquid chromatography (HPLC or LC) with tandem mass spectrometry detection (MS/MS) as previously described. 19 Briefly, dGuo was extracted from the supernatant using a Waters Oasis "HLB" affinity solid phase extraction (SPE) cartridge. The mass of dGuo plus H+ (268.1 m/z) was monitored in quadrupole one (Q1). The dGuo product ion 157.0 m/z was monitored in quadrupole three (Q3). The concentrations of dGuo were determined by weighted (1/x) quadratic regression analysis of peak areas produced from the standard curve.
In-vitro forodesine, ara-G and ara-C cytotoxicity (MTT assay)
Forodesine (36 T-ALL, 43 BCP-ALL and 17 AML samples), ara-G (28 T-ALL, 35 BCP-ALL and 17 AML samples) and ara-C (28 T-ALL samples) cytotoxicities were determined using the MTT assay as described previously. 26 Ara-G is the active metabolite of the pro-drug nelarabine. We measured cell viability in the presence of 1 μM forodesine and 6 concentrations (0.01, 0.1, 1, 3, 10 and 50 μM) of dGuo, following an incubation period of four days. As control, samples were incubated with the same range of dGuo concentrations in the absence of forodesine. Additional controls were 1 μM forodesine in the absence of dGuo, and vehicle only. dGuo is added to the culture to mimic the natural variable presence of dGuo in the blood, as this compound mediates forodesine cytotoxicity. For ara-G (Carbosynth Limited, Berkshire, UK) the following concentrations were used: ara-G 0.01, 0.1, 1, 3, 10, 50 μM. The concentrations used in the MTT assay for ara-C were: 0.01, 0.04, 0.16, 0.625, 2.5 and 10 μM.
Combination cytotoxicity assay
Using the MTT assay as previously described 26 , we screened for potential antagonistic or synergistic effects in forodesine mediated cytotoxicity for 7 compounds that are used in ALL treatment, comprising ara-C, ara-G, 6MP (Sigma Aldrich, St. Louis, USA), asparaginase (Medac, Augusta, USA), daunorubicin (cerubidine®, Sanofi-aventis, Bridgewater, USA), prednisolone (BUFA BV, Uitgeest, the Netherlands), and vincristine (TEVA pharmachemie, Haarlem, the Netherlands). Four to 9 T-ALL and 6 to 8 BCP-ALL pediatric patient samples were tested for each drug combination. Prior to this, the median concentration that is lethal to 10% (LC10) and to 30% (LC30) of cells were determined for dGuo in the presence of 1 μM forodesine on the basis of in-vitro forodesine cytotoxicity assay results (see above) for 10 T-ALL and 10 BCP-ALL patient samples. The T-ALL and BCP-ALL median LC10 or LC30 concentrations were used in the combination assay for T-ALL and BCP-ALL samples, respectively. Forodesine (1μM) and the median LC10 or LC30 concentrations of dGuo were then combined with a range of each of the 7 drugs (ara-C: 0.01, 0.04, 0.16, 0.625, 2.50, 10.0 μM, ara-G: 0.01, 0.10, 1.0, 3.0, 10, 50 μM, 6-mercaptopurine (6MP): 0.016, 0.031, 0.063, 0.125, 0.50, 1.0 mg/ml, asparaginase: 0. 003, 0.016, 0.08, 0.40, 2.0, 10.0 IE/ml, daunorubicin: 0.002, 0.008, 0.031, 0.125, 0.5, 2.0 μg/ml, prednisolone: 0.008, 0.06, 0.49, 3.9, 31.3, 250 μg/ml and vincristine: 0.05, 0.20, 0.78, 3.1, 12.5, 50 .0 μg/ml). The controls were: 1 μM forodesine in combination with the median LC10 or LC30 value of dGuo. Previous experiments on T-ALL cell lines (JURKAT, HPB-ALL, LOUCY and PF-382) showed no effect of addition of the median LC30 values of dGuo on the cytotoxicity of the 7 drugs in the absence of forodesine (data not shown). Since 6MP solutions give a background signal in the MTT assay, varying concentrations of 6MP in culture medium were included as an additional control. For each patient and each concentration of compound tested, a hypothetical maximal additive effect of either LC10 or LC30 forodesine/dGuo treatment in combination with the other compound was calculated by the following formula: ((100-A) X 
RESULTS
In-vitro forodesine and ara-G cytotoxicity levels
To explore the efficacy of purine nucleosides analogues as a potential therapeutic drug for ALL, we tested in-vitro toxicity levels of forodesine and ara-G on pediatric ALL and AML samples. Forodesine toxicity depends on the plasma availability of dGuo and its conversion into dGTP, and we first tested the ability of forodesine to block the degradation of dGuo into guanosine and deoxyribose-1-phosphate by PNP. These measurements were performed in the presence of dGuo and increasing forodesine concentrations. Without forodesine, dGuo levels in the culture media are rapidly being depleted as consequence of PNP-mediated degradation to nearly undetectable levels within 24 hrs in 5 out of 6 patient samples. For all samples tested, 1 μM of forodesine was sufficient to block PNP activity (supplementary figure 1) resulting in the complete stabilization of dGuo levels in the culture supernatants. This dose of forodesine was then chosen in subsequent cellular cytotoxicity experiments.
We then measured the cellular toxicity to 1 μM forodesine in 96 pediatric primary leukemia samples in the presence of varying concentrations of dGuo (Figures 2A and 2B ).
In our assay, dGuo itself elicited no cellular toxicity up to concentrations of 10 μM as it is rapidly being degraded by PNP (data not shown). One μM of forodesine in the absence of dGuo had no effect on survival (data not shown). However, in the presence of forodesine and subsequent blockage of PNP activity, T-ALL samples were more sensitive to dGuo levels (median LC50 = 1.6μM dGuo) than BCP-ALL (median LC50 = 8.8μM dGuo, p=0.001) and AML (median LC50 >10μM, p<0.001) samples ( For personal use only. on January 27, 2018. by guest www.bloodjournal.org1 3
As conversion of dGuo and ara-G rely on the same enzymatic pathways, we investigated potential cross-resistance towards dGuo/forodesine and ara-G in T-ALL patient samples. Patient that require drug concentrations higher than 10µM of dGuo (at 1µM of forodesine) or 50µM of ara-G as LC50 values in our assay were regarded as resistant. We did not find any correlation between dGuo/forodesine and ara-G cytotoxicities, nor between dGuo/forodesine and the pyrimidine equivalent of the ara-G drug, i.e. ara-C ( Figure 3A and 3B). For T-ALL patients, 2 out of 3 samples that were resistant to ara-G were sensitive to forodesine/dGuo exposure whereas 6 out of 7 forodesine/dGuo resistant samples remained sensitive for ara-G. For all patient samples tested, 10 out of 30 ara-G resistant samples remained sensitive to forodesine/dGuo exposure and 19 out of 39 forodesine/dGuo resistant samples were still sensitive to ara-G exposure. Therefore, resistance to ara-G exposure did not preclude sensitivity to forodesine/dGuo exposure and vice versa, and suggests that the modes of cytotoxicity or resistance between forodesine and ara-C or ara-G are different. In contrast, LC50 values for ara-C and ara-G cytotoxicities strongly correlated (p<0.001, R=0.72; Figure 3C ), indicating that the cytotoxic mechanisms are the same for ara-G and ara-C compounds.
dGTP accumulation
To investigate whether differences in forodesine sensitivity levels could be attributed to differences in intracellular accumulation of dGTP, we analysed dGTP levels among patient samples in the absence or presence of forodesine. After 24 hours, no significant differences were found in proliferation rate or the number of apoptotic cells between forodesine/dGuotreated or dGuo-treated control cells (not shown). Without blocking PNP activity, T-ALL patient samples accumulated higher basal intracellular dGTP levels within 24 hours than BCP-ALL samples (p=0.004) ( Figure 4A ), so BCP-ALL cells may have a higher intrinsic ability to degrade dGuo levels than T-ALL cells or have a slower conversion rate of dGuo into dGTP). Upon blockage of PNP by forodesine, total intracellular dGTP levels increased 10 to 100-fold within 24 hours ( Figure 4B) . No difference was observed between T-ALL and BCP-1 4 ALL samples indicating that both ALL types are equally efficient to convert dGuo into dGTP.
Intracellular dGTP accumulation was significantly higher for forodesine sensitive cells than for resistant cells (p=0.001, Figure 4C) . So, resistant patients may convert less dGuo into dGTP or resistant patients more efficiently consume (toxic) dGTP levels.
Gene expression
To find potential explanations for differences in forodesine or ara-G sensitivity levels, we determined mRNA expression levels of different transporters and enzymes that are involved in the purine metabolism (Figure 1) . Of the 13 genes investigated, 4 genes (CNT1, CNT2, CNT3, NT5C1A) were expressed at low to undetectable levels in most of our patient samples and were therefore excluded from further analyses. ENT1 and ENT2 were both expressed at higher levels in T-ALL samples than in BCP-ALL samples (p=0.007 and p=0.036 respectively) while levels of the nucleotidase NT5C2/PNT5 and PNP were expressed at lower levels (p=0.016 and p<0.001, respectively; Figure 5 ).
Patient samples sensitive to forodesine/dGuo expressed higher levels of dGK (p=0.039; Figure 6A ), and may more efficiently convert dGuo into dGMP as a first activation step in the conversion of dGuo into dGTP. ENT1 and ENT2 levels were significantly higher in ara-G sensitive patients than in resistant patients (p=0.010 and p=0.009, respectively; Figure   6B ) permitting a higher uptake of ara-G. ENT1 expression levels strongly correlated with ara-G sensitivity levels (p=0.005 R=-0.503). Also for T-ALL samples, we found a correlation between ENT1 levels and ara-C sensitivity (p=0.011 R=-0.60). Strikingly, ENT1 and ENT2 levels were not related to forodesine sensitivity, indicating that cellular uptake of forodesine may be facilitated by another transporter.
Combination studies
In the treatment of leukemia, multiple drugs are administered simultaneously or administered sequentially. It is therefore important to test for drug interactions. To this end we explored the presence of synergistic, additive or antagonistic effects between forodesine/dGuo and 7
For personal use only. on January 27, 2018. by guest www.bloodjournal.org From other compounds that are currently used in ALL treatment protocols. Leukemic cells were incubated with a concentration range of these 7 compounds with or without the LC10 or LC30 cytotoxic dGuo concentrations (0.02μM and 0.48μM for T-ALL and 0.5 μM and 3.5 μM for BCP-ALL, respectively) in the presence of 1μM of forodesine. As controls, samples were incubated with LC10 or LC30 concentrations of dGuo with 1μM forodesine only. For prednisone, vincristine, and asparaginase, no significant synergistic or antagonistic effects were found in combination with forodesine/dGuo. To our surprise, no antagonism was observed between forodesine/dGuo and ara-G or ara-C despite the fact that these drugs depend on the same enzymes of the guanosine salvage pathway. For daunorubicin, addition of LC10 forodesine/dGuo levels resulted in an increase of cellular viability, both for T-ALL as well as for BCP-ALL samples (42% vs 61% for T-ALL (p=0.009) and 45% vs 66% for BCP-ALL (p=0.018). This effect was only observed at a daunorubicin concentration of 0.125 μg/ml 
DISCUSSION
In this study, we have demonstrated selective toxicity of forodesine/dGuo treatment for pediatric T-ALL compared to BCP-ALL and AML samples. The median forodesine/dGuo LC50 value was more than 5 fold lower for T-ALL than for BCP-ALL samples. Only one out of 17 AML patients reached an LC50 below 10µM. This patient was also a Down syndrome patient, a syndrome known to display increased sensitive to a wide range of drugs and these patients are highly susceptibility towards toxic side effects 30, 31 . High sensitivity of pediatric T-ALL patients towards forodesine/dGuo exposure is in line with expectations, as natural occurring PNP deficiency is known to result in T-cell lymphopenia 12, 13 , and provided the rationale to develop PNP inhibitors for treatment of T-cell malignancies. Forodesine is a very potent inhibitor of PNP that inhibits PNP activity in the picomolar range in biochemical experiments 32 . Cytotoxic effects of forodesine were shown on T-ALL cell lines before 7 , and a clinical response has been documented in a phase I trial for advanced T-cell malignancies 19 .
Our in-vitro studies indicated that 1μM of forodesine is sufficient to inhibit PNP activity in a cellular system, which is well within clinical achievable plasma concentrations. Steady-state forodesine levels that range between 4 to 8 µM were documented in the plasma of patients following intravenous infusion of 40 mg/m 2 of forodesine 19 . In this clinical phase I trial, elevated dGuo levels up to 34 µM in plasma were documented. As the median LC50 dGuo levels (in the presence of 1 µM of forodesine) in our study for forodesine responsive T-ALL samples was estimated on 1.6 µM (range 0.31-10 µM), this indicates that forodesine may be a promising compound in future clinical trials for nearly 75 percent of pediatric T-ALL patients.
In the present study, we demonstrate that nearly half of all BCP-ALL patient samples responded to dGuo/forodesine with dGuo LC50 values that ranged between 0.67 and 10 µM.
Again, this is well within clinical achievable plasma dGuo levels following forodesine infusion, suggesting that forodesine treatment may be effective for nearly 50 percent of BCP-ALL samples.
7
Selective T-cell toxicity was also demonstrated for the arabinoguanosine derivative compound ara-G. Primary T-ALL patient samples had a median LC50 value of 20.5 μM ara-G whereas about half of BCP-ALL or AML samples did not reach an LC50 within the limits of our assay. T-cell selective toxicity of ara-G is in line with previous studies [14] [15] [16] [17] 33 , and nelarabine is an approved drug for T-cell malignancies 23 . One of the explanations for selective T-cell toxicity by forodesine/dGuo or ara-G treatment is the finding that T-ALL samples express less PNP, which is in line with our previous finding that T-ALL cells have lower PNP activity compared to BCP-ALL cells 34 . Also, the expression of cytosolic purine 5-prime nucleotidase NT5C2 was lower in T-ALL cells than in BCP-ALL cells, so T-ALL cells have a reduced capacity to revert phosphorylation of dGuo. The expression of the equilibrative nucleoside transporters ENT1 and ENT2 was higher for T-ALL than for BCP-ALL cells, possibly resulting in enhanced cellular uptake of dGuo and ara-G. Lower expression levels of PNP and NT5C2 but higher expression of ENT1 and ENT2 transporters in T-ALL cells are in line with our finding of higher basal intracellular dGTP levels after exposure to dGuo in T-ALL patient samples than in BCP-ALL samples. However, following inhibition of PNP activity by forodesine, both responding T-ALL and BCP-ALL samples seem equally efficient to accumulate comparable levels of intracellular dGTP. So, differential sensitivity for T-ALL and B-ALL cells towards forodesine may not be due to differences in the dGuo to dGTP activation steps in the purine salvage pathway, but may be due to differential cytotoxic effects of accumulated dGTP levels on ribonucleotide reductase activity and inhibition of DNA synthesis, or intrinsic differences in the apoptotic thresholds between T-cell and B-cells.
Although dGuo mediated toxicity through forodesine and ara-G toxicity depends on stepwise phosphorylation steps in the purine salvage pathway, no relationship could be demonstrated between forodesine/dGuo sensitivity and ara-G sensitivity. This was further supported by the fact that resistance to ara-G exposure did not preclude sensitivity for forodesine/dGuo or vice versa. In contrast, sensitivity levels towards ara-G strongly correlated with ara-C sensitivity levels. Despite the fact that T-ALL samples have different 1 8 expression levels of enzymes and transporters that favour preferential phosphorylation of dGuo or ara-G in T-ALL cells compared to BCP-ALL cells, our results imply that toxicity levels for both compounds are determined by different components in the purine salvage pathway. For this, dCK has been suggested as an important and rate-limiting factor in the phosphorylation of pyrimidine and purine deoxynucleosides 9 that has been associated with ara-C resistance [35] [36] [37] [38] or relapse 39, 40 . However, we did not observe differences in dCK expression levels between forodesine/dGuo sensitive and resistant patients, nor between ara-G sensitive and resistant patients. In our previous study on infant BCP-ALL, a 2 fold lower expression in dCK levels was identified despite a 3.3 fold higher sensitivity levels towards ara-C compared to non-infant ALL patients 25 . This indicates that dCK is not a major contributer to ara-C, ara-G or forodesine/dGuo toxicity, even when non-physiological high levels of deoxycytidine can block ara-G toxicity 14,17 .
We observed significant differences in the mitochondrial deoxyguanosine kinase (dGK) expression levels between forodesine/dGuo sensitive and resistant patient samples, but not between ara-G sensitive and resistant patients. This finding is completely in line with previous findings by Gandhi and co-workers who demonstrated that dGuo is predominantly phosphorylated by dGK but not by dCK, whereas ara-G can be phosphorylated by both enzymes with dGK as preferential enzyme at limiting ara-G concentrations 41 . Ara-G resistance could be associated with significant lower expression levels of the ENT1 and ENT2 transporters. These transporters have been shown important for the import of ara-C
42
, and elevated ENT1 levels have been reported to explain the high ara-C sensitivity of infant ALL, and a strong correlation was observed between ENT1 expression levels and ara-C sensitivity 25 . Lower ENT1 expression levels have been related to ara-C resistance in childhood AML
29
. Previous work by Huang et al 43 on the T-ALL cell line CCRF-CEM demonstrated that while the cellular uptake of forodesine was dependent on ENT1 and ENT2, forodesine toxicity was not. This is in agreement with our data, and ENT1 and ENT2 expression levels were not related to forodesine toxicity levels. These data therefore suggest that forodesine import and subsequent PNP inhibition seems not limited in leukemia cells but The combination cytotoxicity assays revealed no antagonistic or synergistic effect of forodesine/dGuo combined with prednisone, vincristine or asparaginase. For daunorubicin we observed an antagonistic effect, but only at a single concentration combined with the LC10, but not with the concentration of LC30 forodesine/dGuo. We found no antagonistic effect for forodesine/dGuo with either the purine analogue ara-G, nor with the pyrimidine analogue ara-C. Moreover forodesine/dGuo had a synergistic effect in T-ALL with another purine analogue, 6MP, at multiple concentrations combined with the LC10 and LC30 dGuo/forodesine concentrations. The molecular basis of these differences in combined effects remains elusive.
We conclude that forodesine and ara-G have cytotoxic effects on T-ALL and to a lesser extent on BCP-ALL cells in-vitro and could therefore have potential beneficial therapeutic effects in both types of leukemia, possibly in a combined therapy approach. In AML patients forodesine treatment is expected to result in little response. Our study gives no indication of clear antagonistic effects of forodesine/dGuo when combined with any of the 7 drugs as currently used in leukemia therapy. 
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